Antimicrobials in Gynaecological Practice

Patabendige M a, Herath RP b, Wijesooriya WRPLI c

Abstract
Surgical site infections are a common complication of Gynaecological surgeries. Up to 8-10% of Gynaecological patients undergoing an operative procedure will develop a surgical site infection. In surgeries with high rates of post-operative infection, antibiotic prophylaxis can play a major role in improving outcomes. In addition there are many indications where antimicrobial treatment is necessary in day-to-day Gynaecological practice. This review summarizes the available medical literature to assess the indications and appropriate antimicrobials for common circumstances in Gynaecological practice.

Key Words: Antibiotic use, Gynaecological surgery, surgical site infection.

INTRODUCTION
Out of all patients undergoing Gynaecological surgery 8–10% would develop surgical site infections, which have shown to increase morbidity and mortality, readmission, increase health care cost and length of hospital stay. Appropriate and timely antibiotic prophylaxis has been shown to be highly effective in reducing the incidence of surgical site infections. Other factors to consider when choosing an appropriate prophylactic for prophylaxis include low toxicity, an established safety record, cost and the ability to reach an effective concentration in the relevant tissue prior to the procedure and local epidemiology of causative agents and their resistant patterns. Though antibiotic prophylaxis or empirical antibiotic therapy is based on above facts, the antibiotic regimens should always be adjusted as per culture results and antibiotic sensitivity pattern of the samples collected when relevant.

This article summarizes current recommended practice of antimicrobial use in Gynecological practice according to the available evidences and guidelines. The objective of this article is to provide a guide on the use of antimicrobials in Gynaecological practice.

ABDOMINAL Hysterectomy

This is a clean, contaminated surgery and single course of prophylactic antibiotics is recommended. The benefit of antibiotic prophylaxis in reducing postoperative infection is well established for both vaginal and abdominal hysterectomy. It should be noted that randomized trials of antibiotic prophylaxis for laparoscopic total hysterectomy and laparoscopically assisted hysterectomy have not yet been performed. Bacterial vaginosis is a risk factor for infection after hysterectomy. A randomized non-blinded controlled trial found that treatment with rectal metronidazole for women with bacterial vaginosis significantly reduced the rates of vaginal cuff infection post hysterectomy. The available evidence suggests that all patients should be screened and treated for bacterial vaginosis prior to undergoing hysterectomy. Patients should receive antibiotic prophylaxis for hysterectomy including an antibiotic with an anaerobic coverage. Multiple doses of antibiotic are not more effective than a single antibiotic dose prior to incision.

Primary therapy includes single dose of cefuroxime 1.5 g (intravenous) IV and metronidazole 500mg IV. Alternative therapies are a combination of gentamicin 4-6mg/kg IV and metronidazole 500mg IV or a single dose of co-amoxiclav 1.2g IV. If there is a history of pelvic inflammatory disease or suspected sexually transmitted infections add oral doxycycline 100mg at least one hour prior to surgery followed by 200mg 6 hours after the procedure.

In addition to antibiotic prophylaxis, it is essential to look for all factors that affect the infectious risk. Adherence to appropriate skin preparation procedure, including hair clipping as opposed to shaving by razors, and effective antisepsis of both patient and staff are required. Sterile surgical fields must be ensured, and ongoing quality assessment of sterilization technique, air ventilation, and postoperative wound care is needed.

Consistent infection control surveillance and reporting of infectious complications can minimize these morbidities and possibly to identify clusters of infection and the emergence of antibiotic resistant organisms. This will dictate changes to operative routines and to respond to evolving microbial diversity that seems inevitable.

EVACUATION OF RETAINED PRODUCTS OF CONCEPTION

Primary therapy is a single dose of cefuroxime 1.5g IV and metronidazole 500mg IV combination or else a single dose of co-amoxiclav 1.2g IV. Alternative treatment option includes a
single dose of clindamycin 600mg IV 5. However, prophylactic antibiotics are not recommended for medical termination of pregnancy 5.

**BACTERIAL VAGINOSIS**

Primary therapy is oral metronidazole 400mg 12 hourly for 7 days 12. Alternative treatment options are metronidazole gel 0.75%, one full applicator (5g) intravaginally, once a day for 5 days or clindamycin cream 2%, one full applicator (5g) intravaginally at bedtime for 7 days 13.

**SEPTIC MISCARRIAGE**

Primary therapy is a combination of cefuroxime 750mg IV 8 hourly and metronidazole 500mg IV 8 hourly with or without gentamicin 5-7mg/kg IV once daily 5. Co-amoxiclav 1.2g IV 8 hourly and gentamicin 5mg/kg IV once daily is another option. Add doxycycline if sexually transmitted infection is suspected 5. Alternative therapy is ceftriaxone 2g IV daily and metronidazole 500mg IV 8 hourly or else clindamycin 600mg IV 8 hourly and gentamicin 5-7mg/kg IV once daily 5. Add doxycycline if sexually transmitted infection is suspected 5.

**PELVIC INFLAMMATORY DISEASE OUTPATIENT REGIMEN- FOR MILD TO MODERATE DISEASE**

Primary therapy is ceftriaxone 500 mg intramuscular (IM) single dose and oral doxycycline 100mg 12 hourly for 14 days and metronidazole 400mg 12 hourly for 14 days 5, 14. Alternative therapy (in pregnancy) includes ceftriaxone 500 mg IM single dose with oral azithromycin 1g single dose and oral metronidazole 400mg 12 hourly for 14 days 5, 13. Contact tracing and treatment is indicated in all patients 5.

If the etiology is of non-sexually acquired, another option is oral co-amoxiclav 625mg 8 hourly and oral doxycycline 100mg 12 hourly with oral metronidazole 400mg 12 hourly for 14 days 5. Oral azithromycin 1g single dose can be given instead of doxycycline 5, 13.

**INPATIENT REGIMEN- FOR SEVERE DISEASE**

Clinical experience should guide decisions regarding transition to oral therapy, which usually can be initiated within 24–48 hours of clinical improvement 13. In women with tubo-ovarian abscesses, at least 24 hours of inpatient observation is recommended 13. Primary therapy is ceftriaxone 1g IV daily with oral doxycycline 100mg 12 hourly and oral metronidazole 400mg 12 hourly for 14 days 5. However, when tubo-ovarian abscess is present, clindamycin (450 mg orally 6 hourly) or metronidazole (500 mg twice daily) should be used to complete at least 14 days of therapy with doxycycline to provide more effective anaerobic coverage than doxycycline alone 13. Alternative treatment option is co-amoxiclav 1.2g IV 8 hourly with ciprofloxacin 400mg IV 12 hourly and metronidazole 500mg IV 12 hourly. Therapy should be continued at least for total of 14 days and switch to oral therapy with clinical improvement 5.

**VAGINAL CANDIDIASIS**

**ACUTE UNCOMPROMICATED VAGINAL CANDIDIASIS**

Primary therapy includes topical clotrimazole pessary 500mg single dose at night or clotrimazole pessary 200mg for three nights/100mg for six nights or else clotrimazole 10% cream 5g intravaginally stat 13. Miconazole 100 mg vaginal suppository, one suppository daily for 14 days can also be given 13. Alternative treatment options are oral fluconazole 150mg single dose or else oral itraconazole 200mg 12 hourly 2 doses 5, 13. Oral therapy is indicated when intolerant to topical treatment, severe infection or recurrent infection 5. During pregnancy oral therapy should be avoided. Need to treat symptomatic partners as well.

**RECURRENT VAGINAL CANDIDIASIS**

If there are four or more episodes occurring per year oral therapy is preferred 13. Fluconazole 150mg weekly for six months is recommended 5. Recommendation is a longer duration of initial therapy (e.g., 7–14 days of topical therapy or a 100mg, 150mg or 200mg oral dose of fluconazole every third day for a total of three doses; Day 1, 4, and 7) to attempt mycologic remission before initiating a maintenance antifungal regimen 13. Oral fluconazole (i.e., 100mg, 150mg or 200mg dose) weekly for six months is the first line maintenance regimen 13. If this regimen is not feasible, topical treatments used intermittently can also be considered 13.

The women need to have high vaginal swab for culture, as certain non-albicans Candida spp are developing resistance to azoles 5, 13.

**POST-OPERATIVE WOUND INFECTIONS AFTER ABDOMINAL SURGERIES**

Recommended regimen is doxycycline 100 mg orally twice a day for 21 days 13. Alternatively regimen is Erythromycin base 500 mg orally four times a day for 21 days 13.

**NON-GONOCOCCAL CERVICITIS**

Primary therapy is azithromycin 1g single dose or else doxycycline 100mg 12 hourly for 7 days 13.

**SYPHILIS**

**EARLY SYPHILIS (PRIMARY, SECONDARY AND EARLY LATENT)**

Primary therapy is benzathine penicillin 2.4MU IM single dose 5. Data to support use of alternatives to penicillin in the treatment of primary and secondary syphilis are limited 13. Alternatively doxycycline 100mg 12 hourly for 14 days or tetracycline 500mg 6 hourly for 14 days, can be given to women with penicillin allergy 13. Azithromycin as a single 2 g oral dose has been effective for treating primary and secondary syphilis in some populations 13.

**LATE SYPHILIS (LATE LATENT SYPHILIS, SYPHILIS OF UNKNOWN DURATION, GUMMATOUS SYPHILIS AND CARDIOVASCULAR SYPHILIS)**

Primary therapy is benzathine penicillin 2.4 MU IM weekly for 3 weeks 13. Alternatively therapy includes doxycycline 100mg 12 hourly for 28 days or tetracycline 500mg 6 hourly for 28 days and these regimes can be used in penicillin allergy 13. The effectiveness of alternatives to penicillin in the treatment of latent syphilis has not been well documented 13.
NEUROSYPHILIS
Primary therapy is benzathine penicillin 4 MU IV every 4 hours for 14 days 13. Alternative therapy is procaine penicillin G 2.4 MU IM once daily and probenecid 500 mg orally four times a day for 14 days 13.

TRICHOMENASA
Primary therapy is metronidazole 2g orally in a single dose or tinidazole 2g orally in a single dose 13. Alternative therapy includes metronidazole 400 mg orally twice a day for 7 days 13.

OTHER COMMON GYNAECOLOGICAL PROCEDURES
Antibiotic prophylaxis is not recommended for insertion of intrauterine contraceptive devices, hysteroscopy, diagnostic laparoscopy and laparoscopic sterilization 4,17,45. Furthermore antibiotic prophylaxis is not recommended for hysterosalpingography (HSG) without a prior history of pelvic inflammatory disease 4,44. Infection after HSG occurs in a small number of women and reported rates are 1.4–3.4% 25. It is also not recommended in Large Loop Excision of Transformation Zone (LLETZ) 26. A recent Dutch study on hysteroscopy conducted in an outpatient setting in asymptomatic women with infertility found an infection rate of 0.4% without antibiotic prophylaxis 27.

However, based on above studies antibiotic prophylaxis should be instituted in any of the procedures mentioned above if there is a reason to suspect infection risk or if the findings at the procedure indicate risk of infection e.g. dilated fallopian tubes at HSG and a history of PID 28. Doxycycline is the usual recommended agent and is continued for five days to treat presumed PID. Single-dose azithromycin is an acceptable alternative 8. There is debate on the value of routine prophylactic antibiotics for midurethral sling procedures for urinary incontinence due to lack of evidence to give a recommendation 29. Broad spectrum antibiotics should be used during major abdominal, laparoscopic or vaginal procedures 28.

AUTHORS’ CONTRIBUTIONS
MP designed and wrote the paper. Both RPH and WRPLIW contributed for editing the paper. All authors accepted the final version to be published.

Table 1: Strategies to prevent laparoscopic port site infections.
<table>
<thead>
<tr>
<th>Strategies to prevent laparoscopic port site infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Use of disposable trocars and instruments.</td>
</tr>
<tr>
<td>2. Adequate availability of properly sterilised reusable trocars to cover all</td>
</tr>
<tr>
<td>the surgical procedures in a day.</td>
</tr>
<tr>
<td>3. Use of autoclavable laparoscopic hand instruments.</td>
</tr>
<tr>
<td>4. Use of instruments with good ergonomics, limited joints and facility for</td>
</tr>
<tr>
<td>proper cleaning of the debris collected in its crevices.</td>
</tr>
<tr>
<td>5. A proper cleaning of the instrument is best achieved by ultrasonic technology.</td>
</tr>
<tr>
<td>6. Use of autoclaved water for cleaning the instruments after dismantling.</td>
</tr>
<tr>
<td>7. Proper guidelines should be followed regarding the concentration, contact</td>
</tr>
<tr>
<td>time and cycles of use for instrument sterilization with liquid sterilizing</td>
</tr>
<tr>
<td>agents.</td>
</tr>
<tr>
<td>8. Use of plasma sterilizer or ethylene oxide in between the consecutive surgery</td>
</tr>
<tr>
<td>for instrument sterilization.</td>
</tr>
<tr>
<td>9. Avoiding inter-departmental sharing of instruments, such as using instruments</td>
</tr>
<tr>
<td>used for gynecological or urological procedures.</td>
</tr>
<tr>
<td>10. Avoiding spillage of bile or gut content in the operative area or the port</td>
</tr>
<tr>
<td>site.</td>
</tr>
<tr>
<td>11. Use of non-porous specimen retrieval bags for retrieving the specimen.</td>
</tr>
<tr>
<td>12. Thorough irrigation and cleaning of the port site before wound closure.</td>
</tr>
</tbody>
</table>

CONFLICTS OF INTEREST AND FINANCIAL DISCLOSURE
There are no conflicts of interest and no relevant sources of funding.

REFERENCES
9. Larsson PG, Karlsson B. Does pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with...


